Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance
Our study presents the discovery of an anti-CD47/CD24 bispecific antibody that offers a promising therapeutic strategy to address the challenges associated with both the efficacy and safety of CD47-targeting agents, offers insight into macrophage-driven cancer immunotherapy, and could potentially provide a therapeutic option for patients non-responsive to immunotherapy.
Authors
- Shaogang Peng
- Liandi Chen
- Wei-Feng Huang (ORCID: https://orcid.org/0000-0002-9755-7299)
- Xiaomu Wang (ORCID: https://orcid.org/0009-0001-3084-5747)
- Xiaoniu Miao (ORCID: https://orcid.org/0000-0002-5285-5823)
- H Liao (ORCID: https://orcid.org/0000-0003-2168-706X)
- Zhao Cui (ORCID: https://orcid.org/0000-0002-5837-1926)
- Yanqing Lv (ORCID: https://orcid.org/0000-0002-7206-4885)
- Lidi Nan (ORCID: https://orcid.org/0009-0001-8645-6142)
- Yifei Wang (ORCID: https://orcid.org/0000-0002-2073-2837)
- Chao Wang (ORCID: https://orcid.org/0000-0002-8054-3472)
- Yi Luo (ORCID: https://orcid.org/0009-0002-7438-4011)
- Juan Zhang (ORCID: https://orcid.org/0000-0003-1067-7878)
- Andy Tsun
Institutions
- China Pharmaceutical University (CN)
- Shanghai Jiao Tong University (CN)
- Suzhou Electrical Apparatus Science Academy (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-013283
- Citations
- 2
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.59